Earlier today
Week In Review: Abbisko Sells China Rights For CSF-1R Inhibitor To Merck In $605M Deal Seeking Alpha02:24
In the last 7 days
Merck (MRK) Shares Cross 3% Yield Mark Nasdaq15:54 8-Dec-23
Merck and Eisai's Keytruda-Lenvima combo comes up short yet again, this time in endometrial… FiercePharma12:39 8-Dec-23
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study Zacks11:04 8-Dec-23
Merck expects low impact from China restrictions Taipei Times10:48 8-Dec-23
Merck-Eisai uterine cancer drug combination fails first-line treatment study Proactive Investors (US)09:37 8-Dec-23
Merck’s Keytruda Flops in Late-Stage Endometrial Carcinoma Study BioSpace09:21 8-Dec-23
Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in Metastatic Squamous NSCLC to Stop for Futility OncLive09:14 8-Dec-23
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer Benzinga08:36 8-Dec-23
Fierce Pharma Asia—WuXi Bio's plunge; Daiichi-Novartis $182M settlement; Merck KGaA's Abbisko… FiercePharma08:25 8-Dec-23
Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial MarketWatch08:03 8-Dec-23
Merck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet Endpoints RTT News07:51 8-Dec-23
AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer PMLiVE07:28 8-Dec-23
Merck, Eisai: Keytruda/Lenvima Combo Fails in 1st-Line Endometrial Cancer Study MarketWatch07:11 8-Dec-23
Merck-Eisai's uterine cancer therapy combo fails first-line treatment trial Reuters07:08 8-Dec-23
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus… Business Wire (Press Release)06:47 8-Dec-23
Merck collaborates with Acceleration Consortium for AI experimentation Pharmafile06:39 8-Dec-23
Ex-Cedilla CEO Glucksmann explores ‘new frontier’ at Sensorium; R&D chief out at Merck women’s health spinoff Organon ENDPOINTS05:56 8-Dec-23
Merck to discontinue Phase III lung cancer trial due to futility Clinical Trials Arena05:40 8-Dec-23
Merck Navigates Chip Geopolitics With ‘China For China’ Strategy BNN Bloomberg05:15 8-Dec-23
Three phase IIIs: BMS, Merck and Sanofi release new cancer data BioWorld17:18 7-Dec-23
Merck halts trial after Keytruda-Lynparza combo flunks PhIII study in lung cancer ENDPOINTS14:21 7-Dec-23
Merck’s Keytruda, Anti-TIGIT Combo Fails Phase II NSCLC Trial BioSpace11:51 7-Dec-23
Merck cancels Phase 3 lung cancer study on disappointing interim data Proactive Investors (US)11:45 7-Dec-23
Merck cancels Phase 3 lung cancer study on disappointing interim data as separate mid-stage… Proactive Investors (US)11:35 7-Dec-23
Merck & Co. digs into TIGIT fail, sharing survival data from phase 2 lung cancer trial FierceBiotech10:07 7-Dec-23
For Merck, Lynparza fails to improve on Keytruda in first-line lung cancer FiercePharma09:43 7-Dec-23
Double Flops For Merck's Lung Cancer Studies Benzinga09:43 7-Dec-23
Abbisko out-licenses pimicotinib to Merck KGaA in $605M deal BioWorld09:17 7-Dec-23
Merck Scraps Phase 3 Keytruda-Lynparza Lung Cancer Study The Wall Street Journal07:43 7-Dec-23
Merck details PhII TIGIT/PD-1 fail in lung cancer ENDPOINTS07:25 7-Dec-23
Meniscus Tear Market Growth Anticipated by 2032 | Major Players: Merck, Teva Pharmaceutical,… Industry Today07:11 7-Dec-23
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA®… Business Wire (Press Release)06:55 7-Dec-23
Merck Reports Data From Phase 2 KeyVibe-002 Trial - Quick Facts RTT News06:34 7-Dec-23
Merck's lung cancer drug combo fails to meet trial goal Reuters06:23 7-Dec-23
Lack Of Efficacy, Not Safety, Dooms Merck KGaA’s BTK Inhibitor Scrip Pharma Intelligence04:12 7-Dec-23
Efficacy, Not Safety, Dooms Merck KGaA’s BTK Inhibitor Scrip Pharma Intelligence18:32 6-Dec-23
(Favezelimab + pembrolizumab) by Merck for Metastatic Transitional (Urothelial) Tract Cancer:… Pharmaceutical Technology12:55 6-Dec-23
Merck KGaA’s experimental MS drug fails in late stage trials Proactive Investors (US)11:49 6-Dec-23
Merck KGaA’s experimental MS drug fails in late stage trials sending shares tumbling Proactive Investors (US)11:29 6-Dec-23
Efficacy, Not Safety, Does For Merck KGaA’s BTK Inhibitor Scrip Pharma Intelligence10:43 6-Dec-23
Merck Collaborates with Acceleration Consortium on Open-Sourcing AI-Driven Experimentation Planner AsiaOne10:00 6-Dec-23
Merck partners with HiberCell for Phase Ib renal carcinoma trial Pharmaceutical Technology09:51 6-Dec-23
Merck Group Stock Plummets After MS Drug Fails Late-Stage Trials The Messenger08:59 6-Dec-23
Merck a Top 25 Dividend Giant With 2.90% Yield (MRK) Nasdaq08:39 6-Dec-23
Interstitial Cystitis Market Growth Anticipated by 2032 | Major Players: Merck, Teva… Industry Today08:27 6-Dec-23
Merck Collaborates with Acceleration Consortium on Open-Sourcing AI-Driven ... Merck Group (Press Release)08:06 6-Dec-23
Merck gains rights to Abbisko’s pimicotinib in deal worth over $70m PMLiVE07:49 6-Dec-23
Merck KGaA’s BTK Inhibitor Fails Phase III Multiple Sclerosis Studies BioSpace07:21 6-Dec-23
Merck KGaA’s evobrutinib disappoints in PhIII multiple sclerosis test, casting dark cloud over BTK class ENDPOINTS07:13 6-Dec-23
Europe midday: Gains held on rate cut bets; Merck, Tui in focus ShareCast07:08 6-Dec-23
Merck shares sink after MS drug fails in latest trial ShareCast06:38 6-Dec-23
Merck’s multiple sclerosis therapy trials fail to meet primary goals Clinical Trials Arena06:21 6-Dec-23
Merck KGaA Plunges as Multiple Sclerosis Drug Fails in Trial (3) Bloomberg Law06:01 6-Dec-23
Merck pummelled as MS hope fenebrutinib dies in phase 3 pharmaphorum05:13 6-Dec-23
Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials MarketWatch04:50 6-Dec-23
Merck KGaA’s BTK drug flunks pivotal multiple sclerosis trials, sending shockwaves through the… FierceBiotech04:50 6-Dec-23
Europe open: Shares up on rate cut bets; Merck tanks on MS trial failure ShareCast04:04 6-Dec-23
Merck Faces Major Setback as MS Drug Fails TipRanks03:47 6-Dec-23
Merck MS Drug Misses Late-Stage Trial Target The Wall Street Journal03:34 6-Dec-23
Daiichi Sankyo and Merck ink ADC codevelopment deal Chemical & Engineering News03:20 6-Dec-23
Merck MS Drug Fails to Meet Target of Late-Stage Trials MarketWatch01:16 6-Dec-23
Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis Business Wire (Press Release)17:57 5-Dec-23
Merck KGaA, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in… Business Wire (Press Release)17:57 5-Dec-23
Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple ... Merck Group (Press Release)16:40 5-Dec-23
Merck KGaA’s Multiple Sclerosis Drug Fails Final-Stage Studies BNN Bloomberg16:30 5-Dec-23
Merck KGaA says MS drug fails in late-stage trials Reuters16:02 5-Dec-23
Abbisko out-licenses China rights for pimicotinib to Merck KGaA in $605M deal BioWorld13:34 5-Dec-23
Synovial Sarcoma Market to Accelerate Substantially During the Study Period (2019–2032), Assesses DelveInsight | Key… GlobeNewswire (Press Release)13:02 5-Dec-23
Dow Analyst Moves: MRK Nasdaq12:00 5-Dec-23
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer BioSpace10:10 5-Dec-23
Merck signs $70 million deal to commercialize Abbisko’s new cancer drug in China Outsourcing-Pharma.com09:52 5-Dec-23
Gossamer Bio taps Bob Smith from Merck as new commercial lead as it rolls the dice on… FiercePharma08:43 5-Dec-23
Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis Merck Group (Press Release)08:00 5-Dec-23
Merck signs deal to commercialise Abbisko Therapeutics’ pimicotinib Pharmaceutical Technology03:25 5-Dec-23
Sacituzumab tirumotecan by Merck for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood… Pharmaceutical Technology23:32 4-Dec-23
Nedisertib by Merck for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval Pharmaceutical Technology21:49 4-Dec-23
Ex-FBI Trainee Pleads Guilty to Trading on Confidential Deal Information BNN Bloomberg12:30 4-Dec-23
Merck grabs late-stage oncology drug from China’s Abbisko pharmaphorum11:32 4-Dec-23
Former FBI Agent Trainee Pleads Guilty to Insider Trading Scheme FBI (Press Release)11:06 4-Dec-23
Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront FierceBiotech10:27 4-Dec-23
Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug ENDPOINTS10:04 4-Dec-23
Abbisko Therapeutics Announces Licensing Agreement For Pimicotinib With Merck - Quick Facts RTT News08:46 4-Dec-23
Merck to Pay at Least $70 Mln for Rights to Abbisko Joint-Tumor Drug MarketWatch08:42 4-Dec-23
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck BioSpace08:24 4-Dec-23
Merck Strengthens Oncology Portfolio Through Commercialization Agreement With ... Merck Group (Press Release)08:05 4-Dec-23
Merck Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase … Business Wire (Press Release)08:01 4-Dec-23
Merck KGaA, Darmstadt, Germany Strengthens Oncology Portfolio Through Commercialization… Business Wire (Press Release)08:01 4-Dec-23
Global Blood Group Typing Market Size To Worth USD 3.98 Billion by 2032 | CAGR of 8.4% GlobeNewswire (Press Release)05:50 4-Dec-23
In the last month
FDA accepts Merck’s Keytruda plus Padcev sBLA to treat urothelial cancer Pharmaceutical Technology05:30 1-Dec-23
Big Pharma is ‘reeling’ over the Inflation Reduction Act. Now Merck is fighting back The News Tribune, Washington04:28 1-Dec-23
Price Over Earnings Overview: Merck & Co Benzinga14:11 30-Nov-23
Merck turns to Acclinate to increase African American participation in cancer trials FierceBiotech09:10 30-Nov-23
After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset FierceBiotech08:09 30-Nov-23
Merck shares positive phase 3 results for investigational pneumococcal vaccine in adults PMLiVE07:40 30-Nov-23
Acclinate Collaborates with Merck to Increase Clinical Trial Diversity PR Newswire (Press Release)06:00 30-Nov-23
Merck's Korean subsidiary wins prime minister's citation Korea JoongAng Daily03:37 30-Nov-23
‘Merck at the forefront of addressing Korea's infertility issue’ Korea Biomedical Review19:30 29-Nov-23
Assistance program now available for uninsured patients at CHCC Marianas Variety09:22 29-Nov-23
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate… Business Wire (Press Release)09:03 29-Nov-23
Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study Zacks07:38 29-Nov-23
Merck reports data from Phase III pneumococcal vaccine trial Clinical Trials Arena05:51 29-Nov-23
Merck integrates p-Chip Corp's MicroTransponder technology Med-Tech Innovation05:09 29-Nov-23
Merck and p-Chip bridge gap between physical and digital trust layers New Electronics17:54 28-Nov-23
Merck Raises Quarterly Dividend 5.5% To 77c MarketWatch13:48 28-Nov-23
Merck raises quarterly dividend to 77 cents vs. 73 cents MarketWatch13:27 28-Nov-23
Merck Announces First-Quarter 2024 Dividend Business Wire (Press Release)13:26 28-Nov-23
Triple-Negative Breast Cancer Market to Grow Rapidly During the Forecast Period (2023–2032), Predicts DelveInsight |… GlobeNewswire (Press Release)13:05 28-Nov-23
How is Patent Term Extension Calculated For a Reissued Patent? JD Supra12:02 28-Nov-23
Merck stokes pneumococcal rivalry with Pfizer, revealing updated 21-valent vaccine data ENDPOINTS10:40 28-Nov-23
Kenneth Frazier on His Unlikely Path to Merck CEO, the Current State of the Profession and More Law.com Corporate Counsel10:29 28-Nov-23
Merck strides onto Pfizer’s turf, posting pivotal vaccine data and heading to regulators FierceBiotech08:32 28-Nov-23
Dr. Liu Jian, President of Medicilon Drug Discovery Division, wins the Thomas Alva Edison… PR Newswire (Press Release)08:32 28-Nov-23
Merck and p-Chip close the gap between physical and digital trust layers Merck Group (Press Release)08:05 28-Nov-23
Nanochemicals Global Industry Market Trends, Growth, Opportunity and Forecasts 2023-2028 with Profiles of Azelis, BASF, … GlobeNewswire (Press Release)04:21 28-Nov-23

      
            
      
    view more headlines
   
      
      
      
10 Dec 02:24
   
Merck & Co News

NewsNow aims to be the world's most accurate and comprehensive aggregator of Merck & Co news, covering the latest MSD share price, Merck Sharp & Dohme company announcements, product trials, pharmaceutical news and more from the best online publications. Every story from every site is brought to you automatically and continuously 24/7, within around 10 minutes of publication.
Merck & Co

Latest News

Merck & Co News

Pharmaceuticals Top Stories

Business Top Stories
